Stoke Therapeutics, Inc.
STOK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001623526
In the last 90 days, Stoke Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 197 institutions reported holding it in 13F filings for Q2 2026, worth $2.49B in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Stoke Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 97 | 1 | 81 | −15 |
| Shares | 43.8M | 14.9K | 45.0M | +1.22M (+2.8%) |
| Value | $173.1M | $58.7K | $236.9M | +$63.8M (+36.9%) |
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held Stoke Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 50,786 | $267.1K | 0.00% |
| Susquehanna Portfolio Strategies, LLC | 45,108 | $237.3K | 0.00% |
| Bridgeway Capital Management, LLC | 17,100 | $89.9K | 0.00% |
| Zacks Investment Management | 14,064 | $74.0K | 0.00% |
| Qube Research & Technologies Ltd | 35 | $184 | 0.00% |
| The PNC Financial Services Group, Inc. | 5 | $26 | 0.00% |
Sold out (21)
Institutions that held Stoke Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Wellington Management Group LLP | 174,332 | $686.9K |
| Mirae Asset Global Investments Co., Ltd. | 146,076 | $575.5K |
| Simplify Asset Management Inc. | 102,985 | $405.8K |
| Walleye Capital LLC | 67,351 | $265.4K |
| Marshall Wace, LLP | 48,001 | $189.1K |
| Swiss National Bank | 43,300 | $170.6K |
| Alps Advisors Inc | 32,647 | $128.6K |
| Tudor Investment Corp Et Al | 18,252 | $71.9K |
| Verition Fund Management LLC | 15,255 | $60.1K |
| Allspring Global Investments Holdings, LLC | 14,790 | $58.3K |
| Corton Capital Inc. | 14,749 | $58.1K |
| Credit Suisse AG | 12,449 | $49.0K |
| Sherbrooke Park Advisers LLC | 12,295 | $48.4K |
| UBS Asset Management Americas Inc | 11,398 | $44.9K |
| Virtus ETF Advisers LLC | 7,893 | $31.1K |
| China Universal Asset Management Co., Ltd. | 1,132 | $4.46K |
| Federated Hermes, Inc. | 1,076 | $4.24K |
| US Bancorp | 538 | $2.12K |
| Quadrant Capital Group LLC | 221 | $871 |
| Beaird Harris Wealth Management, LLC | 38 | $150 |
| Daiwa Securities Group Inc. | 126 | $0 |
Not filed for Q4 2023 yet (1)
Institutions that held Stoke Therapeutics, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Virginia Retirement Systems Et Al | 14,900 | $58.7K |